Archive for the ‘field’ tag
Leading Eye Institute to Participate in ACT’s Embryonic Stem Cell Clinical Trial for Macular Degeneration
Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today announced that the Wills Eye Institute in Philadelphia has received insti
Follow this link:
Leading Eye Institute to Participate in ACT’s Embryonic Stem Cell Clinical Trial for Macular Degeneration
Advanced Cell Technology to Present at 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Advanced Cell Technology, Inc.
See the original post:
Advanced Cell Technology to Present at 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum
Advanced Cell Technology to Present at 2011 Stem Cell Meeting on the Mesas Investor and Partnering Forum
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company’s director of business development, Matthew Vincent, Ph.D., will be presenting at the 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum, Nov. 30 to Dec
International Stem Cell Corporation Announces Third Quarter 2011 Financial Results
International Stem Cell Corporation (ISCO) (OTCBB:ISCO) today announced financial results for the three-month and nine-month periods ended September 30, 2011. ISCO is a development-stage biotechnology company that created, patented and is commercializing a powerful new stem cell technology called parthenogenesis which promises to advance significantly the field of regenerative medicine.
Read the original post:
International Stem Cell Corporation Announces Third Quarter 2011 Financial Results
US stem cell pioneer abandons ‘costly’ research
STEM cell therapy pioneer Geron is to abandon stem cell research because of high costs and commercial uncertainties for the field.
Geron shares fall after company drops stem cells
Shares of stem cell therapy pioneer Geron Corp. plunged Tuesday morning after the company said it would abandon stem cell research because of the high costs and commercial uncertainties for the field.
Read more here:
Geron shares fall after company drops stem cells
Stem cell study helps clarify the best time for therapy to aid heart attack survivors
Physicians have found that stem cells obtained from bone marrow delivered two to three weeks after a person has a heart attack did not improve heart function. This is the first study to systematically examine the timing and method of stem cell delivery and provides vital information for the field of cell therapy.
More here:
Stem cell study helps clarify the best time for therapy to aid heart attack survivors
European Ruling May Not Impact Stem Cell Lines Derived Using Advanced Cell Technology’s Single-Blastomere Method
Advanced Cell Technology, Inc.
The rest is here:
European Ruling May Not Impact Stem Cell Lines Derived Using Advanced Cell Technology’s Single-Blastomere Method
BioTime CEO Michael D. West to Present at GTC 2011 5th Advances in Stem Cell Discovery & Development Conference
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that …
Go here to see the original:
BioTime CEO Michael D. West to Present at GTC 2011 5th Advances in Stem Cell Discovery & Development Conference
Regenerative Medicine and Applications of Stem Cell Research
(June 1, 2010) Renee Reijo Pera, Ph.D., and Professor Michael Longaker discuss the future of regenerative medicine and the promise that stem cell research holds for this field. During the final quarter of the Stanford Mini Med School, some of the most timely and important topics in contemporary medicine and the biosciences are addressed.
Go here to see the original:
Regenerative Medicine and Applications of Stem Cell Research